DAFNA Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-321,856
| Closed | -$9.69K | – | 83 |
|
|
2022
Q4 | $9.69K | Hold |
321,856
| – | – | ﹤0.01% | 79 |
|
|
2022
Q3 | $57K | Sell |
321,856
-56,755
| -15% | -$57.9K | 0.02% | 87 |
|
|
2022
Q2 | $227K | Hold |
378,611
| – | – | 0.06% | 84 |
|
|
2022
Q1 | $500K | Hold |
378,611
| – | – | 0.13% | 82 |
|
|
2021
Q4 | $988K | Sell |
378,611
-224,431
| -37% | -$678K | 0.25% | 64 |
|
|
2021
Q3 | $1.88M | Hold |
603,042
| – | – | 0.5% | 52 |
|
|
2021
Q2 | $2.24M | Hold |
603,042
| – | – | 0.47% | 45 |
|
|
2021
Q1 | $2.09M | Buy |
603,042
+282,500
| +88% | +$1.15M | 0.5% | 48 |
|
|
2020
Q4 | $1.08M | Hold |
320,542
| – | – | 0.32% | 58 |
|
|
2020
Q3 | $1.13M | Hold |
320,542
| – | – | 0.37% | 54 |
|
|
2020
Q2 | $1.47M | Hold |
320,542
| – | – | 0.43% | 46 |
|
|
2020
Q1 | $1.06M | Sell |
320,542
-40,000
| -11% | -$183K | 0.44% | 46 |
|
|
2019
Q4 | $2.2M | Hold |
360,542
| – | – | 0.76% | 32 |
|
|
2019
Q3 | $1.5M | Buy |
360,542
+160,529
| +80% | +$1.28M | 0.57% | 46 |
|
|
2019
Q2 | $2.62M | Buy |
200,013
+127,513
| +176% | +$1.56M | 0.99% | 29 |
|
|
2019
Q1 | $689K | Sell |
72,500
-27,500
| -28% | -$109K | 0.3% | 60 |
|
|
2018
Q4 | $309K | Buy |
+100,000
| New | +$396K | 0.15% | 71 |
|
DAFNA Capital Management's PHAS Position: Q1 2023 in Review
DAFNA Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2023, closing a stake of 321,856 shares — an estimated $9.69K sold.
DAFNA Capital Management first reported a position in PHAS in Q4 2018 and held it in 17 quarters. The position peaked at $2.62M in Q2 2019. 0 funds tracked by Wall St. Rank hold PHAS as of Q1 2023.
- DAFNA Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- DAFNA Capital Management sold 321,856 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $9.69K.
- DAFNA Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 17 quarters.
- DAFNA Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.62M in Q2 2019.
- 0 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.